Bioengineering breakthroughs: The impact of stem cell models on advanced therapy medicinal product development.

IF 3.6 3区 医学 Q3 CELL & TISSUE ENGINEERING
José Mauro Granjeiro, Priscila Grion de Miranda Borchio, Icaro Paschoal Brito Ribeiro, Katiucia Batista Silva Paiva
{"title":"Bioengineering breakthroughs: The impact of stem cell models on advanced therapy medicinal product development.","authors":"José Mauro Granjeiro, Priscila Grion de Miranda Borchio, Icaro Paschoal Brito Ribeiro, Katiucia Batista Silva Paiva","doi":"10.4252/wjsc.v16.i10.860","DOIUrl":null,"url":null,"abstract":"<p><p>The burgeoning field of bioengineering has witnessed significant strides due to the advent of stem cell models, particularly in their application in advanced therapy medicinal products (ATMPs). In this review, we examine the multifaceted impact of these developments, emphasizing the potential of stem cell models to enhance the sophistication of ATMPs and to offer alternatives to animal testing. Stem cell-derived tissues are particularly promising because they can reshape the preclinical landscape by providing more physiologically relevant and ethically sound platforms for drug screening and disease modelling. We also discuss the critical challenges of reproducibility and accuracy in measurements to ensure the integrity and utility of stem cell models in research and application. Moreover, this review highlights the imperative of stem cell models to align with regulatory standards, ensuring using stem cells in ATMPs translates into safe and effective clinical therapies. With regulatory approval serving as a gateway to clinical adoption, the collaborative efforts between scientists and regulators are vital for the progression of stem cell applications from bench to bedside. We advocate for a balanced approach that nurtures innovation within the framework of rigorous validation and regulatory compliance, ensuring that stem cell-base solutions are maximized to promote public trust and patient health in ATMPs.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 10","pages":"860-872"},"PeriodicalIF":3.6000,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525646/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of stem cells","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4252/wjsc.v16.i10.860","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

The burgeoning field of bioengineering has witnessed significant strides due to the advent of stem cell models, particularly in their application in advanced therapy medicinal products (ATMPs). In this review, we examine the multifaceted impact of these developments, emphasizing the potential of stem cell models to enhance the sophistication of ATMPs and to offer alternatives to animal testing. Stem cell-derived tissues are particularly promising because they can reshape the preclinical landscape by providing more physiologically relevant and ethically sound platforms for drug screening and disease modelling. We also discuss the critical challenges of reproducibility and accuracy in measurements to ensure the integrity and utility of stem cell models in research and application. Moreover, this review highlights the imperative of stem cell models to align with regulatory standards, ensuring using stem cells in ATMPs translates into safe and effective clinical therapies. With regulatory approval serving as a gateway to clinical adoption, the collaborative efforts between scientists and regulators are vital for the progression of stem cell applications from bench to bedside. We advocate for a balanced approach that nurtures innovation within the framework of rigorous validation and regulatory compliance, ensuring that stem cell-base solutions are maximized to promote public trust and patient health in ATMPs.

生物工程的突破:干细胞模型对先进治疗药物产品开发的影响。
由于干细胞模型的出现,特别是在先进治疗药物产品(ATMP)中的应用,蓬勃发展的生物工程领域取得了长足进步。在这篇综述中,我们研究了这些发展的多方面影响,强调干细胞模型在提高ATMP复杂性和提供动物试验替代品方面的潜力。干细胞衍生组织特别有前景,因为它们可以为药物筛选和疾病建模提供更符合生理和伦理要求的平台,从而重塑临床前的格局。我们还讨论了测量中可重复性和准确性的关键挑战,以确保干细胞模型在研究和应用中的完整性和实用性。此外,本综述强调干细胞模型必须符合监管标准,确保在ATMP中使用干细胞转化为安全有效的临床疗法。监管批准是临床应用的关口,科学家与监管机构之间的合作对于干细胞应用从实验室走向临床至关重要。我们主张采取一种平衡的方法,在严格验证和监管合规的框架内培育创新,确保最大限度地利用干细胞基础解决方案,促进公众对ATMP的信任和患者健康。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
World journal of stem cells
World journal of stem cells Biochemistry, Genetics and Molecular Biology-Molecular Biology
CiteScore
7.80
自引率
4.90%
发文量
750
期刊介绍: The World Journal of Stem Cells (WJSC) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of stem cells. It was launched on December 31, 2009 and is published monthly (12 issues annually) by BPG, the world''s leading professional clinical medical journal publishing company.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信